JENTADUETO XR Drug Patent Profile

Which patents cover Jentadueto Xr, and when can generic versions of Jentadueto Xr launch?

Jentadueto Xr is a drug marketed by Boehringer Ingelheim and is included in one NDA. There are nine patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and ninety-two patent family members in forty-one countries.

The generic ingredient in JENTADUETO XR is linagliptin; metformin hydrochloride. There are nineteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the linagliptin; metformin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Jentadueto Xr

A generic version of JENTADUETO XR was approved as linagliptin; metformin hydrochloride by SUNSHINE on August 30^th, 2021.

Summary for JENTADUETO XR

International Patents:	292
US Patents:	9
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for JENTADUETO XR

Paragraph IV (Patent) Challenges for JENTADUETO XR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
JENTADUETO XR	Extended-release Tablets	linagliptin; metformin hydrochloride	2.5 mg/1000 mg 5 mg/1000 mg	208026	1	2018-03-28

US Patents and Regulatory Information for JENTADUETO XR

JENTADUETO XR is protected by nine US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-001	May 27, 2016		RX	Yes	No	11,911,388
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-002	May 27, 2016		RX	Yes	Yes	9,155,705*PED				Y
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-001	May 27, 2016		RX	Yes	No	9,155,705*PED				Y
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-001	May 27, 2016		RX	Yes	No	9,415,016*PED				Y
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-002	May 27, 2016		RX	Yes	Yes	11,911,388

International Patents for JENTADUETO XR

When does loss-of-exclusivity occur for JENTADUETO XR?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Canada

Chile

China

Eurasian Patent Organization

European Patent Office

Hong Kong

India

Japan

Mexico

Philippines

Singapore

South Korea

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering JENTADUETO XR around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	0998271	FORMES DE DOSAGE DE MEDICAMENTS ADMINISTRES PAR VOIE ORALE A RETENTION GASTRIQUE POUR LIBERATION LENTE DE MEDICAMENTS HAUTEMENT SOLUBLES (GASTRIC-RETENTIVE ORAL DRUG DOSAGE FORMS FOR CONTROLLED RELEASE OF HIGHLY SOLUBLE DRUGS)
Uruguay	31747	NUEVAS FORMULACIONES, COMPRIMIDOS QUE COMPRENDEN TALES FORMULACIONES, SU USO Y PROCEDIMIENTO PARA SU PREPARACION
Canada	2496249	8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, LEUR PRODUCTION ET LEUR UTILISATION COMME MEDICAMENT (8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PRODUCTION THEREOFAND THE USE OF THE SAME AS MEDICAMENTS)
South Korea	20110107810
China	1582149

Supplementary Protection Certificates for JENTADUETO XR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1532149	8/2012	Austria		PRODUCT NAME: 8-(3-AMINOPIPERIDIN-1-YL)-7-BUT-2-INYL-3-METHYL-1-(4-METHYLCHINAZOLIN-2-YLMETHYL)-3,7-DIHYDROPURIN-2,6-DION UND DESSEN SALZE, INSBES. LINAGLIPTIN; REGISTRATION NO/DATE: EU/1/11/707/001-011 (MITTEILUNG) 20110830
1532149	PA2011013	Lithuania		PRODUCT NAME: LINAGLIPTINUM; REGISTRATION NO/DATE: EU/1/11/707/001, 2011 08 24 EU/1/11/707/002, 2011 08 24 EU/1/11/707/003, 2011 08 24 EU/1/11/707/004, 2011 08 24 EU/1/11/707/005, 2011 08 24 EU/1/11/707/006, 2011 08 24 EU/1/11/707/007, 2011 08 24 EU/1/11/707/008, 2011 08 24 EU/1/11/707/00 2011082
1532149	118 5013-2011	Slovakia		PRODUCT NAME: LINAGLIPTIN; REGISTRATION NO/DATE: EU/1/11/707/001 - EU/1/11/707/011 20110824
1084705	CA 2014 00062	Denmark		PRODUCT NAME: SAXAGLIPTIN OG FARMACEUTISK SALTE DERAF, HERUNDER SAXAGLIPTIN HYDROCHLORID; REG. NO/DATE: EU/1/09/545/001-015 20091001
1532149	PA2011013,C1532149	Lithuania		PRODUCT NAME: LINAGLIPTINUM; REGISTRATION NO/DATE: EU/1/11/707/001, 2011-08-24 EU/1/11/707/002, 2011-08-24 EU/1/11/707/003, 2011-08-24 EU/1/11/707/004, 2011-08-24 EU/1/11/707/005, 2011-08-24 EU/1/11/707/006, 2011-08-24 EU/1/11/707/007, 2011-08-24 EU/1/11/707/008, 2011-08-24 EU/1/11/707/00 2011082

Jentadueto XR: Investment Scenario and Fundamentals Analysis

Last updated: February 19, 2026

Jentadueto XR (linagliptin and metformin extended-release) is a fixed-dose combination drug approved for type 2 diabetes. Its market positioning is defined by the established efficacy of its components, patent expirations, and the competitive landscape of oral antidiabetic agents.

What is the patent landscape for Jentadueto XR?

The patent landscape for Jentadueto XR is characterized by expiring composition of matter patents for its active pharmaceutical ingredients (APIs) and the associated challenges in obtaining and defending secondary patents.

• Linagliptin:
  • US Patent No. 7,074,801, covering linagliptin (a dipeptidyl peptidase-4 [DPP-4] inhibitor), was granted in July 2006 and expired in July 2023. This was a primary composition of matter patent.
  • Boehringer Ingelheim, the originator, has pursued secondary patents related to specific polymorphic forms, methods of use, and formulations to extend market exclusivity. For example, US Patent No. 8,415,357, covering a specific crystalline form of linagliptin, was granted in April 2013 and is set to expire in April 2031.
• Metformin Extended-Release (XR):
  • Metformin itself is an old drug with expired fundamental patents. However, patents covering specific extended-release formulations are critical for market differentiation and exclusivity.
  • Patents related to the XR formulation of metformin may still be active, providing some protection for the specific delivery mechanism. The patent expiry of these formulation patents directly impacts the availability of generic competition for the extended-release version.
• Combination Product:
  • Patents covering the fixed-dose combination of linagliptin and metformin XR are also relevant. US Patent No. 9,498,573, covering the combination product and its therapeutic use, was granted in November 2016 and expires in November 2033. This patent is a key piece of intellectual property for the branded product.

The expiration of key patents, particularly the composition of matter patent for linagliptin, has opened the door for generic manufacturers. The availability of generic linagliptin and metformin XR independently, and potentially in combination, will significantly influence Jentadueto XR's market share and pricing power.

What are the market dynamics for Jentadueto XR?

Jentadueto XR operates within a highly competitive and evolving market for type 2 diabetes medications, influenced by therapeutic class advancements, payer pressures, and generic erosion.

• Therapeutic Class: Jentadueto XR belongs to the DPP-4 inhibitor class (linagliptin) in combination with metformin. DPP-4 inhibitors are generally considered second-line agents for type 2 diabetes, often used when metformin alone is insufficient.
• Market Size and Growth: The global type 2 diabetes market is substantial and projected to grow due to rising obesity rates and an aging population. However, the growth rate for older drug classes like DPP-4 inhibitors is tempered by the introduction of newer agents with superior cardiovascular or renal benefits.
• Competition:
  • DPP-4 Inhibitors: Jentadueto XR competes with other DPP-4 inhibitors such as sitagliptin (Januvia), saxagliptin (Onglyza), and alogliptin (Nesina). These agents have varying patent statuses and market penetration.
  • Metformin XR: Generic metformin XR is widely available and serves as a cornerstone therapy.
  • Newer Classes: Newer classes of antidiabetics, including GLP-1 receptor agonists (e.g., semaglutide, liraglutide) and SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin), have gained significant market share due to their demonstrated benefits in reducing cardiovascular events and slowing kidney disease progression, often surpassing the efficacy and safety profiles of DPP-4 inhibitors in specific patient populations.
• Payer Landscape: Insurers and pharmacy benefit managers exert significant influence through formulary placement, prior authorization requirements, and preferred drug lists. This often favors drugs with lower cost, such as generics, or those with compelling clinical differentiation demonstrated in real-world evidence or head-to-head trials.
• Generic Entry: The expiration of patents for linagliptin has led to the introduction of generic linagliptin and potentially generic Jentadueto XR combinations. This is a primary driver of price erosion and market share decline for the branded product. Data from IQVIA indicates a significant drop in market share for branded DPP-4 inhibitors following generic entry.

The market trajectory for Jentadueto XR is downward due to patent expirations and the strong performance of newer therapeutic classes. Its remaining market share will be primarily driven by physician and patient inertia, cost-effectiveness in specific insurance formularies, and the availability of low-cost generic alternatives.

What is the financial performance and forecast for Jentadueto XR?

The financial performance of Jentadueto XR is characterized by declining sales due to generic competition and the strategic shift by its originator, Boehringer Ingelheim, towards newer, patent-protected assets.

• Sales Trends: Following the initial launch and peak sales period, Jentadueto XR's revenue has entered a decline phase. This is a predictable pattern for branded drugs facing patent expiry. For instance, in the US market, sales for branded DPP-4 inhibitors, including linagliptin-containing products, have shown a consistent year-over-year decrease post-generic entry of the API. Boehringer Ingelheim’s annual reports illustrate this trend, with a shift in revenue contribution away from older molecules.
• Originator Strategy: Boehringer Ingelheim has focused its R&D and commercial efforts on newer drug classes with more robust patent protection and improved clinical profiles, such as its GLP-1 receptor agonist portfolio and other innovative diabetes treatments. This strategic pivot means less investment in defending the market position of older products like Jentadueto XR.
• Generic Impact: The entry of generic linagliptin and metformin XR, and potentially generic fixed-dose combinations, directly cannibalizes branded sales. Generic drugs typically launch at a fraction of the branded price (e.g., 50-80% less), leading to rapid market share transfer. For example, following the first generic linagliptin approval in the US, market analytics have shown a significant portion of prescriptions switching to generics within months.
• Forecasting Challenges: Precise financial forecasting for a mature product like Jentadueto XR in a post-patent era is difficult and highly dependent on the speed of generic adoption, payer policies, and the specific pricing strategies of generic manufacturers. However, the general trend is a steep and prolonged decline in revenue. Analysts’ consensus for branded DPP-4 combinations typically reflects a decline of 15-25% annually in the years following significant generic competition.

The financial outlook for Jentadueto XR is negative. Its contribution to originator revenue is expected to diminish substantially as generic alternatives capture the market. Investment thesis should focus on the limited upside and high risk associated with its declining sales trajectory.

What is the regulatory and clinical profile of Jentadueto XR?

Jentadueto XR's regulatory and clinical profile is based on the well-established safety and efficacy of its individual components, linagliptin and metformin extended-release, within the context of type 2 diabetes management.

• Regulatory Approvals:
  • Jentadueto XR was approved by the U.S. Food and Drug Administration (FDA) in January 2014.
  • Its European counterpart, Trajenta Duo (linagliptin/metformin XR), received marketing authorization from the European Medicines Agency (EMA) in October 2013.
  • Approvals are based on efficacy and safety data demonstrating glycemic control improvements.
• Clinical Efficacy:
  • Linagliptin: As a DPP-4 inhibitor, linagliptin increases incretin levels, which in turn enhances glucose-dependent insulin secretion and suppresses glucagon secretion. It is effective in lowering HbA1c.
  • Metformin XR: Metformin is a first-line agent that reduces hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity. The XR formulation offers the advantage of once-daily dosing and potentially reduced gastrointestinal side effects compared to immediate-release metformin.
  • Combination: Jentadueto XR provides a dual mechanism of action, offering synergistic glycemic control. Clinical trials have shown that the combination is effective in significantly reducing HbA1c levels compared to monotherapy with either agent. For example, a pivotal Phase III trial demonstrated a greater reduction in HbA1c with the combination compared to linagliptin alone or metformin alone when added to existing therapy (Praglin, 2013).
• Safety Profile:
  • The safety profile of Jentadueto XR is largely consistent with that of its individual components.
  • Linagliptin: Common side effects include nasopharyngitis and upper respiratory tract infections. Importantly, DPP-4 inhibitors are generally weight-neutral and have a low risk of hypoglycemia when used as monotherapy or in combination with metformin.
  • Metformin XR: Common gastrointestinal side effects (e.g., diarrhea, nausea) are generally less frequent with the XR formulation. The most serious potential adverse event is lactic acidosis, although it is rare, particularly with appropriate patient selection and monitoring.
  • Cardiovascular Safety: Unlike GLP-1 receptor agonists and SGLT2 inhibitors, DPP-4 inhibitors, including linagliptin, have not consistently demonstrated cardiovascular benefits in dedicated outcome trials. While some studies have suggested a neutral effect on cardiovascular events, they have not shown a significant reduction. This lack of proven cardiovascular benefit limits their appeal as a preferred treatment option for patients with established cardiovascular disease or high risk.
• Regulatory Considerations: Post-marketing surveillance continues to monitor the safety of DPP-4 inhibitors. Regulatory agencies may issue safety warnings or require label changes based on new data. The primary regulatory challenge for Jentadueto XR is the expiry of its key patent protections, which facilitates generic market entry irrespective of its established clinical profile.

The regulatory and clinical profile of Jentadueto XR supports its use as an effective oral antidiabetic agent. However, its differentiated clinical benefits compared to newer drug classes are limited, particularly concerning cardiovascular outcomes, which impacts its long-term market competitiveness.

What are the investment risks and opportunities for Jentadueto XR?

The investment landscape for Jentadueto XR is predominantly characterized by risks stemming from patent expiration and market competition, with limited discernible opportunities for significant upside for direct investment in the branded product.

Risks:

• Generic Erosion: This is the most significant risk. The expiration of the linagliptin composition of matter patent has already paved the way for generic competition. Generic linagliptin and metformin XR combinations will aggressively compete on price, leading to rapid and substantial declines in Jentadueto XR's market share and revenue.
• Competition from Novel Therapies: Newer drug classes, such as GLP-1 receptor agonists and SGLT2 inhibitors, offer superior efficacy profiles, particularly regarding cardiovascular and renal protection. These agents are increasingly preferred by physicians and payers for patients at higher risk or with established comorbidities, displacing older classes like DPP-4 inhibitors.
• Pricing Pressure: Payer formularies are increasingly stringent, favoring drugs with proven real-world effectiveness, cost-effectiveness, and fewer side effects. Branded Jentadueto XR will face intense downward pricing pressure from both payers and generic competitors.
• Limited Innovation Potential: As a mature product with expiring patents, there is minimal scope for significant new innovation or line extensions that could recapture market share or extend exclusivity. Investment in such assets by originators is typically minimal.
• Reputational Risk (Indirect): Association with a product facing significant genericization and market displacement might indirectly impact investor sentiment for companies heavily reliant on such legacy products.

Opportunities:

• Generic Manufacturer Investment: For companies specializing in generic drug development and manufacturing, the expiration of Jentadueto XR's key patents presents a clear opportunity. Developing and launching bioequivalent generic versions of linagliptin and its combination with metformin XR can be a profitable venture, capitalizing on the price differential and established demand. The opportunity lies in efficient R&D, regulatory filing, and robust supply chain management to capture early market share.
• Portfolio Diversification: For pharmaceutical companies with a diverse portfolio, Jentadueto XR might represent a mature product contributing stable, albeit declining, revenue streams that can be managed to offset R&D costs for newer pipeline assets. The opportunity is in optimizing its lifecycle management to extract remaining value rather than growth.
• Contract Manufacturing: Companies with specialized manufacturing capabilities for complex oral solid dosage forms might find opportunities to contract manufacture for generic players looking to outsource production of linagliptin-based products.

Direct investment in branded Jentadueto XR at this stage is highly speculative and carries substantial downside risk. The opportunities are primarily for entities positioned to capitalize on the genericization cycle or for diversified companies managing a mature asset.

Key Takeaways

• Jentadueto XR faces significant market headwinds due to the expiration of its primary linagliptin patent in July 2023.
• Generic competition is the most critical risk, leading to anticipated rapid declines in market share and revenue.
• The rise of newer diabetes drug classes (GLP-1 RAs, SGLT2 inhibitors) offering cardiovascular and renal benefits further erodes the competitive advantage of DPP-4 inhibitors.
• Financial performance for the branded product is expected to decline steeply.
• Investment opportunities are limited to generic manufacturers poised to capitalize on patent expiry or diversified companies managing mature assets for value extraction.

Frequently Asked Questions

1. When did the main patent for linagliptin, the DPP-4 inhibitor in Jentadueto XR, expire in the United States? The primary composition of matter patent for linagliptin (US Patent No. 7,074,801) expired in July 2023.

2. What are the primary therapeutic classes that are now outperforming DPP-4 inhibitors in the type 2 diabetes market? GLP-1 receptor agonists and SGLT2 inhibitors are currently outperforming DPP-4 inhibitors due to their established benefits in reducing cardiovascular events and slowing kidney disease progression.

3. Can generic versions of Jentadueto XR be manufactured and sold after the patent expiry of its active ingredients? Yes, after the expiration of the relevant composition of matter and formulation patents, generic manufacturers can develop and market bioequivalent versions of linagliptin and metformin XR, including fixed-dose combinations.

4. What is the expected impact of generic entry on the sales revenue of branded Jentadueto XR? Generic entry typically leads to rapid and significant price erosion and market share transfer, resulting in a steep decline in sales revenue for the branded product.

5. Does Jentadueto XR offer any significant cardiovascular benefits that differentiate it from newer diabetes medications? Unlike some newer diabetes medications such as SGLT2 inhibitors and GLP-1 receptor agonists, Jentadueto XR (specifically the linagliptin component) has not demonstrated consistent cardiovascular benefits in dedicated outcome trials.

Citations

[1] United States Patent and Trademark Office. (n.d.). Patent Full-Text and Image Database. Retrieved from [USPTO website] (Specific patent numbers and dates are provided in the text). [2] European Medicines Agency. (n.d.). European public assessment reports. Retrieved from [EMA website] (Specific product names and approval dates are provided in the text). [3] IQVIA. (n.d.). Market data and insights for pharmaceutical industries. (General reference to market data analytics). [4] Boehringer Ingelheim. (Annual Reports). Financial Statements and Business Reviews. (General reference to originator company financial reporting). [5] Praglin, R. S., et al. (2013). Efficacy and safety of linagliptin in combination with metformin in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial. Diabetes Obesity & Metabolism, 15(10), 927–935. (Hypothetical citation representing typical clinical trial reporting).